US5015751044
© Globe Newswire
11.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
News Preview
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial ...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
News Preview
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Proposed Public Offering
News Preview
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
08.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
News Preview
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
News Preview
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
News Preview
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.11.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
News Preview
WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: ...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
News Preview
Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
News Preview
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: ...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
News Preview
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.10.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
News Preview
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
News Preview
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.09.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
News Preview
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a hig...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
News Preview
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: ...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
News Preview
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
News Preview
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Proposed Public Offering
News Preview
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock a...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
News Preview
Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
News Preview
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
News Preview
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
News Preview
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: ...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
News Preview
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
News Preview
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
News Preview
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
News Preview
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference i...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.04.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
News Preview
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.04.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
News Preview
WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of div...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
News Preview
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
News Preview
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upco...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
News Preview
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
News Preview
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Co...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
News Preview
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
News Preview
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
News Preview
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
News Preview
WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investo...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.08.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
News Preview
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering of $225 million of shares of its common stock a...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
News Preview
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its common stock and, in l...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
News Preview
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
News Preview
Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.06.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
News Preview
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.06.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
News Preview
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.05.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
News Preview
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
News Preview
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
News Preview
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
News Preview
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
